Symbols / BHVN
BHVN Chart
About
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.53B |
| Enterprise Value | 1.31B | Income | -780.11M | Sales | — |
| Book/sh | -0.16 | Cash/sh | 2.46 | Dividend Yield | — |
| Payout | 0.00% | Employees | 256 | IPO | — |
| P/E | — | Forward P/E | -4.01 | PEG | — |
| P/S | — | P/B | -71.23 | P/C | — |
| EV/EBITDA | -1.70 | EV/Sales | — | Quick Ratio | 2.30 |
| Current Ratio | 2.86 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -7.52 | EPS next Y | -2.88 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-02 | ROA | -106.25% |
| ROE | -5.22% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 132.69M |
| Shs Float | 84.69M | Short Float | 17.12% | Short Ratio | 6.71 |
| Short Interest | — | 52W High | 38.23 | 52W Low | 7.48 |
| Beta | 3.54 | Avg Volume | 2.95M | Volume | 454.55K |
| Target Price | $20.94 | Recom | Buy | Prev Close | $11.86 |
| Price | $11.54 | Change | -2.70% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$20.94
Mean price target
2. Current target
$11.54
Latest analyst target
3. DCF / Fair value
$-56.19
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.54
Low
$9.00
High
$50.00
Mean
$20.94
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-21 | up | RBC Capital | Sector Perform → Outperform | $22 |
| 2026-01-06 | main | Morgan Stanley | Overweight → Overweight | $21 |
| 2025-12-26 | reit | HC Wainwright & Co. | Neutral → Neutral | $11 |
| 2025-12-03 | down | HC Wainwright & Co. | Buy → Neutral | $11 |
| 2025-11-26 | down | UBS | Buy → Neutral | $11 |
| 2025-11-20 | main | JP Morgan | Overweight → Overweight | $15 |
| 2025-11-18 | main | Morgan Stanley | Overweight → Overweight | $26 |
| 2025-11-18 | reit | BTIG | Buy → Buy | $16 |
| 2025-11-13 | main | Citigroup | Buy → Buy | $14 |
| 2025-11-06 | down | Bernstein | Outperform → Market Perform | $9 |
| 2025-11-06 | main | RBC Capital | Sector Perform → Sector Perform | $9 |
| 2025-11-06 | main | BTIG | Buy → Buy | $16 |
| 2025-11-05 | down | William Blair | Outperform → Market Perform | — |
| 2025-11-05 | main | TD Cowen | Buy → Buy | $15 |
| 2025-09-17 | init | Citigroup | — → Buy | $28 |
| 2025-09-16 | main | UBS | Buy → Buy | $26 |
| 2025-09-03 | init | Raymond James | — → Strong Buy | $75 |
| 2025-08-19 | main | BTIG | Buy → Buy | $60 |
| 2025-08-12 | main | Leerink Partners | Outperform → Outperform | $50 |
| 2025-08-12 | main | Morgan Stanley | Overweight → Overweight | $54 |
- Assessing Biohaven (BHVN) Valuation After A Sharp One Year Decline And Recent Three Month Rebound - simplywall.st Wed, 25 Feb 2026 07
- Biohaven Ltd. (BHVN) Stock Analysis: Navigating a Potential 80% Upside in the Biotechnology Sector - DirectorsTalk Interviews ue, 24 Feb 2026 14
- Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance ue, 10 Feb 2026 08
- $BHVN stock is up 16% today. Here's what we see in our data. - Quiver Quantitative ue, 18 Nov 2025 08
- Piper Sandler reiterates Biohaven stock rating on epilepsy trial By Investing.com - Investing.com Nigeria Mon, 23 Feb 2026 22
- Biohaven Announces Proposed Public Offering of Common Shares - PR Newswire ue, 11 Nov 2025 08
- Trading the Move, Not the Narrative: (BHVN) Edition - Stock Traders Daily Mon, 23 Feb 2026 12
- Biohaven Insiders Bet $33 Million on a Turnaround - MarketBeat hu, 20 Nov 2025 08
- Biohaven stock defended despite trial setback (BHVN:NYSE) - Seeking Alpha Fri, 26 Dec 2025 08
- This biotech stock has plummeted over the past year. RBC sees big turnaround ahead - CNBC Wed, 21 Jan 2026 08
- BHVN Stock Tumbled A Whopping 44% Today – What Did The FDA Letter Say? - Stocktwits Wed, 05 Nov 2025 08
- Biohaven Ltd. Stock (BHVN) Opinions on Insider Buying and Public Offering | BHVN Stock News - Quiver Quantitative Mon, 17 Nov 2025 08
- Biohaven Announces Pricing of $175 Million Public Offering of Common Shares - PR Newswire Wed, 12 Nov 2025 08
- Biohaven (BHVN): Assessing Valuation After $175 Million Stock Offering and FDA Setback - Yahoo Finance Sat, 15 Nov 2025 08
- Biohaven Ltd. (BHVN) Stock Analysis: Exploring a Potential 198.62% Upside in Biotechnology - DirectorsTalk Interviews ue, 07 Oct 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3750 | — | — | GENTILE KIMBERLY A | Officer | — | 2026-01-05 00:00:00 | D | nan |
| 1 | 14250 | — | — | CORIC VLADIMIR | Chief Executive Officer | — | 2026-01-05 00:00:00 | D | nan |
| 2 | 4750 | — | — | CAR BRUCE | Officer | — | 2026-01-05 00:00:00 | D | nan |
| 3 | 2500 | — | — | CLARK GEORGE C. | Officer | — | 2026-01-05 00:00:00 | D | nan |
| 4 | 4250 | — | — | BUTEN MATTHEW | Chief Financial Officer | — | 2026-01-05 00:00:00 | D | nan |
| 5 | 17000 | — | Purchase at price 8.52 per share. | CLARK GEORGE C. | Officer | — | 2025-11-17 00:00:00 | I | 144770.0 |
| 6 | 3333333 | — | Purchase at price 7.50 per share. | CHILDS JOHN W | Director | — | 2025-11-13 00:00:00 | I | 24999998.0 |
| 7 | 400000 | — | Purchase at price 7.50 per share. | BAILEY GREGORY HUGH | Director | — | 2025-11-13 00:00:00 | D | 3000000.0 |
| 8 | 666666 | — | Purchase at price 7.50 per share. | CORIC VLADIMIR | Chief Executive Officer | — | 2025-11-13 00:00:00 | I | 4999995.0 |
| 9 | 32700 | — | Purchase at price 30.39 - 30.73 per share. | CHILDS JOHN W | Director | — | 2025-03-04 00:00:00 | I | 996238.0 |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.21 | 0.27 |
| NormalizedEBITDA | -877.26M | -429.14M | -566.55M | -217.51M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -846.42M | -408.17M | -570.28M | -213.80M |
| ReconciledDepreciation | 7.86M | 6.91M | 1.39M | 1.39M |
| EBITDA | -877.26M | -429.14M | -566.55M | -217.51M |
| EBIT | -885.11M | -436.05M | -567.93M | -218.90M |
| NormalizedIncome | -846.42M | -408.17M | -570.28M | -213.80M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -846.42M | -408.17M | -570.28M | -213.80M |
| TotalExpenses | 885.11M | 436.05M | 567.93M | 218.90M |
| TotalOperatingIncomeAsReported | -885.11M | -436.05M | -567.93M | -218.90M |
| DilutedAverageShares | 91.23M | 71.20M | 44.74M | 35.82M |
| BasicAverageShares | 91.23M | 71.20M | 44.74M | 35.82M |
| DilutedEPS | -9.28 | -5.73 | -12.75 | -5.97 |
| BasicEPS | -9.28 | -5.73 | -12.75 | -5.97 |
| DilutedNIAvailtoComStockholders | -846.42M | -408.17M | -570.28M | -213.80M |
| NetIncomeCommonStockholders | -846.42M | -408.17M | -570.28M | -213.80M |
| NetIncome | -846.42M | -408.17M | -570.28M | -213.80M |
| NetIncomeIncludingNoncontrollingInterests | -846.42M | -408.17M | -570.28M | -213.80M |
| NetIncomeContinuousOperations | -846.42M | -408.17M | -570.28M | -213.80M |
| TaxProvision | 735.00K | -1.38M | 438.00K | 1.37M |
| PretaxIncome | -845.69M | -409.55M | -569.84M | -212.43M |
| OtherIncomeExpense | 39.42M | 26.50M | -1.91M | 6.47M |
| OtherNonOperatingIncomeExpenses | 39.42M | 26.50M | -1.91M | 1.21M |
| EarningsFromEquityInterest | 0.00 | 0.00 | 5.26M | |
| OperatingIncome | -885.11M | -436.05M | -567.93M | -218.90M |
| OperatingExpense | 885.11M | 436.05M | 567.93M | 218.90M |
| ResearchAndDevelopment | 795.87M | 373.28M | 437.07M | 181.49M |
| SellingGeneralAndAdministration | 89.24M | 62.77M | 130.86M | 37.41M |
| GeneralAndAdministrativeExpense | 89.24M | 62.77M | 130.86M | 37.41M |
| OtherGandA | 89.24M | 62.77M | 130.86M | 37.41M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 101.22M | 81.12M | 68.19M | 35.82M |
| ShareIssued | 101.22M | 81.12M | 68.19M | 35.82M |
| TotalDebt | 36.58M | 30.88M | 33.60M | 2.80M |
| TangibleBookValue | 403.65M | 408.19M | 518.98M | 14.90M |
| InvestedCapital | 423.44M | 427.98M | 538.77M | 34.69M |
| WorkingCapital | 384.25M | 387.02M | 496.95M | 52.89M |
| NetTangibleAssets | 403.65M | 408.19M | 518.98M | 14.90M |
| CapitalLeaseObligations | 36.58M | 30.88M | 33.60M | 2.80M |
| CommonStockEquity | 423.44M | 427.98M | 538.77M | 34.69M |
| TotalCapitalization | 423.44M | 427.98M | 538.77M | 34.69M |
| TotalEquityGrossMinorityInterest | 423.44M | 427.98M | 538.77M | 94.69M |
| MinorityInterest | 0.00 | 60.00M | ||
| StockholdersEquity | 423.44M | 427.98M | 538.77M | 34.69M |
| OtherEquityInterest | 34.69M | |||
| GainsLossesNotAffectingRetainedEarnings | 79.00K | -65.00K | 284.00K | 0.00 |
| OtherEquityAdjustments | 79.00K | -65.00K | 284.00K | |
| RetainedEarnings | -1.35B | -499.29M | -91.12M | 0.00 |
| AdditionalPaidInCapital | 112.37M | 39.80M | 13.87M | 0.00 |
| CapitalStock | 1.66B | 887.53M | 615.74M | 0.00 |
| CommonStock | 1.66B | 887.53M | 615.74M | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 191.67M | 85.24M | 123.01M | 47.37M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 37.45M | 29.81M | 32.99M | 5.43M |
| OtherNonCurrentLiabilities | 4.66M | 2.25M | 2.41M | 2.64M |
| LongTermDebtAndCapitalLeaseObligation | 32.78M | 27.57M | 30.58M | 2.80M |
| LongTermCapitalLeaseObligation | 32.78M | 27.57M | 30.58M | 2.80M |
| CurrentLiabilities | 154.23M | 55.42M | 90.02M | 41.94M |
| OtherCurrentLiabilities | 84.71M | 11.71M | 3.57M | |
| CurrentDebtAndCapitalLeaseObligation | 3.80M | 3.31M | 3.02M | |
| CurrentCapitalLeaseObligation | 3.80M | 3.31M | 3.02M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 837.00K | 14.60M | 9.54M | |
| PayablesAndAccruedExpenses | 65.71M | 52.12M | 72.40M | 32.40M |
| CurrentAccruedExpenses | 47.69M | 36.54M | 26.48M | 27.62M |
| Payables | 18.03M | 15.58M | 45.91M | 4.78M |
| DuetoRelatedPartiesCurrent | 0.00 | 35.21M | 0.00 | |
| AccountsPayable | 18.03M | 15.58M | 10.70M | 4.78M |
| TotalAssets | 615.11M | 513.21M | 661.78M | 142.06M |
| TotalNonCurrentAssets | 76.64M | 70.77M | 74.81M | 47.24M |
| OtherNonCurrentAssets | 3.13M | 2.40M | 2.58M | 3.22M |
| InvestmentsAndAdvances | 0.00 | 6.00M | ||
| OtherInvestments | 0.00 | 6.00M | ||
| LongTermEquityInvestment | 0.00 | |||
| GoodwillAndOtherIntangibleAssets | 19.79M | 19.79M | 19.79M | 19.79M |
| OtherIntangibleAssets | 18.40M | 18.40M | 18.40M | 18.40M |
| Goodwill | 1.39M | 1.39M | 1.39M | 1.39M |
| NetPPE | 53.71M | 48.58M | 52.44M | 18.23M |
| AccumulatedDepreciation | -12.21M | -8.28M | -4.91M | -3.34M |
| GrossPPE | 65.92M | 56.86M | 57.35M | 21.57M |
| Leases | 824.00K | 802.00K | 0.00 | |
| ConstructionInProgress | 0.00 | |||
| OtherProperties | 36.71M | 31.94M | 37.57M | 5.22M |
| MachineryFurnitureEquipment | 14.31M | 12.39M | 7.48M | 4.05M |
| BuildingsAndImprovements | 14.08M | 11.73M | 12.30M | 12.30M |
| LandAndImprovements | 12.30M | 12.30M | ||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 538.47M | 442.45M | 586.97M | 94.82M |
| OtherCurrentAssets | 508.00K | 12.13M | 19.33M | 2.12M |
| RestrictedCash | 0.00 | 35.21M | 0.00 | |
| PrepaidAssets | 49.38M | 35.24M | 20.95M | 6.73M |
| Receivables | 2.60M | 13.25M | 46.14M | 9.91M |
| TaxesReceivable | 2.60M | 13.25M | 46.14M | 9.91M |
| CashCashEquivalentsAndShortTermInvestments | 485.99M | 381.82M | 465.34M | 76.06M |
| OtherShortTermInvestments | 386.86M | 133.42M | 260.46M | 0.00 |
| CashAndCashEquivalents | 99.13M | 248.40M | 204.88M | 76.06M |
| CashFinancial | 76.06M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -586.50M | -334.77M | -338.76M | -146.78M |
| IssuanceOfCapitalStock | 666.16M | 243.22M | 283.80M | 0.00 |
| CapitalExpenditure | -4.05M | -3.05M | -41.07M | -938.00K |
| InterestPaidSupplementalData | 125.00K | 0.00 | 0.00 | 107.00K |
| IncomeTaxPaidSupplementalData | 38.16M | 16.59M | ||
| EndCashPosition | 102.54M | 252.12M | 242.60M | 77.06M |
| BeginningCashPosition | 252.12M | 242.60M | 77.06M | 83.51M |
| EffectOfExchangeRateChanges | 75.00K | -497.00K | 429.00K | 0.00 |
| ChangesInCash | -149.65M | 10.01M | 165.12M | -6.45M |
| FinancingCashFlow | 677.77M | 211.91M | 767.60M | 138.45M |
| CashFlowFromContinuingFinancingActivities | 677.77M | 211.91M | 767.60M | 138.45M |
| NetOtherFinancingCharges | 108.00K | -36.01M | 483.34M | 138.45M |
| ProceedsFromStockOptionExercised | 11.50M | 4.70M | 451.00K | |
| NetCommonStockIssuance | 666.16M | 243.22M | 283.80M | 0.00 |
| CommonStockIssuance | 666.16M | 243.22M | 283.80M | 0.00 |
| InvestingCashFlow | -244.97M | 129.83M | -304.79M | 944.00K |
| CashFlowFromContinuingInvestingActivities | -244.97M | 129.83M | -304.79M | 944.00K |
| NetInvestmentPurchaseAndSale | -241.32M | 132.88M | -263.72M | 0.00 |
| SaleOfInvestment | 504.36M | 327.00M | 0.00 | 0.00 |
| PurchaseOfInvestment | -745.68M | -194.12M | -263.72M | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | 1.88M | |
| SaleOfBusiness | 0.00 | 0.00 | 1.88M | |
| NetIntangiblesPurchaseAndSale | 391.00K | 0.00 | -35.00M | 0.00 |
| SaleOfIntangibles | 391.00K | 0.00 | 0.00 | |
| PurchaseOfIntangibles | 0.00 | 0.00 | -35.00M | 0.00 |
| NetPPEPurchaseAndSale | -4.05M | -3.05M | -6.07M | -938.00K |
| PurchaseOfPPE | -4.05M | -3.05M | -6.07M | -938.00K |
| OperatingCashFlow | -582.45M | -331.73M | -297.69M | -145.84M |
| CashFlowFromContinuingOperatingActivities | -582.45M | -331.73M | -297.69M | -145.84M |
| ChangeInWorkingCapital | 16.81M | 24.61M | -28.60M | 1.66M |
| ChangeInOtherCurrentLiabilities | 0.00 | 1.94M | ||
| ChangeInOtherCurrentAssets | 0.00 | -109.00K | ||
| ChangeInPayablesAndAccruedExpense | 8.77M | -2.56M | 12.73M | 10.85M |
| ChangeInAccruedExpense | 8.06M | -7.44M | 6.80M | 9.82M |
| ChangeInPayable | 710.00K | 4.87M | 5.93M | 1.02M |
| ChangeInAccountPayable | 710.00K | 4.87M | 5.93M | 1.02M |
| ChangeInPrepaidAssets | 8.04M | 27.18M | -41.34M | -9.18M |
| OtherNonCashItems | 68.48M | 16.13M | 2.50M | 4.52M |
| StockBasedCompensation | 71.96M | 28.79M | 193.56M | 65.64M |
| AssetImpairmentCharge | 0.00 | 0.00 | 10.00M | 0.00 |
| DepreciationAmortizationDepletion | 7.86M | 6.91M | 1.39M | 1.39M |
| DepreciationAndAmortization | 7.86M | 6.91M | 1.39M | 1.39M |
| OperatingGainsLosses | 98.86M | 93.75M | -5.26M | |
| EarningsLossesFromEquityInvestments | 0.00 | 0.00 | -5.26M | |
| GainLossOnInvestmentSecurities | 88.05M | |||
| GainLossOnSaleOfPPE | 10.81M | 0.00 | 93.75M | 0.00 |
| NetIncomeFromContinuingOperations | -846.42M | -408.17M | -570.28M | -213.80M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BHVN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|